ATM alterations have been reported as germline variants which predispose to inherited cancer syndromes and as somatic (acquired) variants in tumors. ATM is part of many signalling networks, including cell metabolism and growth, oxidative stress, and chromatin remodelling, all of which can affect cancer progression. Although ATM is considered to be a tumour suppressor, ATM signaling may be advantageous to cancer cells in some settings, particularly in resistance to radio- and chemotherapeutic treatment. For this reason, the use of ATM inhibitors in cancer therapy is under exploration.
Fletcher et al. Missense Variants in ATM in 26,101 Breast Cancer Cases and 29,842 Controls. Cancer Epidemiol Biomarkers Prev. 2010; 19(9): 2143-2151
Mangone et al. ATM gene mutations in sporadic breast cancer patients from Brazil. SpringerPlus DOI 10.1186/s40064-015-0787-z
Cremona et al. ATM signalling and cancer. Oncogene. 2014; 33:3351-3360
Anika Maria Weber et al. ATM and ATR as therapeutic targets in cancer. Pharmacology & Therapeutics. 2015; 129:124-138
Disclaimer: You assume full responsibility for all risks associated with using this PMKB website. The IPM makes no guarantee of the comprehensiveness, reliability or accuracy of the information on this website and the IPM assumes no responsibility for errors in the information associated with this web site. Healthcare providers and patients must integrate all clinical and laboratory findings as well as information from a variety of sources before deciding on appropriate clinical care options.